Article

Feb e-news images

images

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Related Content
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial
Published: October 12th 2024 | Updated: October 11th 2024

First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial

EyePod: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD
October 11th 2024

Innovation Series: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD

Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300
October 11th 2024

Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

Nanoscope to submit BLA for MCO-010 to treat retinitis pigmentosa
October 10th 2024

Nanoscope to submit BLA for MCO-010 to treat retinitis pigmentosa

AAO 2024 meeting information not to miss
October 10th 2024

AAO 2024 meeting information not to miss

© 2024 MJH Life Sciences

All rights reserved.